Aridis Pharmaceuticals shares are trading higher after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design.
Portfolio Pulse from Benzinga Newsdesk
Aridis Pharmaceuticals announced that it has received FDA agreement for its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design, leading to a rise in its share prices.
May 31, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aridis Pharmaceuticals shares are trading higher after receiving FDA agreement for its proposed Phase 3 study of AR-301.
The FDA agreement for the Phase 3 study of AR-301 is a significant milestone for Aridis Pharmaceuticals. This news is likely to boost investor confidence in the company's ability to advance its drug candidate, leading to a positive short-term impact on its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100